

Practical Perspectives: Experts Review Actual Cases of Patients with Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **The Phase III Ideate-Lung02 trial is currently evaluating ifinatamab deruxtecan (I-DXd) in which of the following settings?**
  - a. In combination with durvalumab following chemoradiation therapy in limited-stage small cell lung cancer (LS-SCLC)
  - b. As first-line therapy in combination with atezolizumab and platinum/etoposide for newly diagnosed extended-stage SCLC (ES-SCLC)
  - c. After 1 prior line of systemic treatment including platinum-based chemotherapy**
  - d. For heavily pretreated ES-SCLC with no satisfactory alternative options
2. **The Phase III IMforte trial is evaluating which of the following treatment strategies for patients with ES-SCLC?**
  - a. First-line atezolizumab versus durvalumab, both in combination with platinum-based chemotherapy
  - b. First-line maintenance therapy with lurbinectedin and atezolizumab**
  - c. Second-line treatment with durvalumab and tarlatamab after disease progression on first-line durvalumab and platinum/etoposide
  - d. Second-line treatment with lurbinectedin after disease progression on first-line chemoimmunotherapy
3. **Which of the following any-grade adverse events (AEs) was most commonly reported with I-DXd for patients with previously treated ES-SCLC in the Phase II Ideate-Lung01 study?**
  - a. Interstitial lung disease
  - b. Pulmonary embolism
  - c. QT interval prolongation
  - d. Nausea**
4. **Which of the following outcomes was observed with adjuvant durvalumab for patients with LS-SCLC in the Phase III ADRIATIC trial?**
  - a. Significant improvement in progression-free survival (PFS) but not overall survival (OS)
  - b. Significant improvement in both PFS and OS**
  - c. No significant improvement in PFS or OS
5. **Which of the following any-grade AEs was most commonly reported with lurbinectedin and atezolizumab as first-line maintenance therapy for patients with ES-SCLC in the Phase III IMforte trial?**
  - a. Neutropenia
  - b. Rash
  - c. Nausea**
  - d. Pneumonia